The purpose of this study is to test the safety and side effects "of "ultra-hypofractionated" radiation therapy when used after brachytherapy (radiation implants). This treatment delivers a higher radiation dose with each treatment over a shorter period of time.
Intermediate risk prostate cancer patients will be eligible for this study. Intermediate risk grouping will be assessed per NCCN guidelines as: Pathologically-proven diagnosis of prostate adenocarcinoma PSA 10-20ng/mL or Gleason =7 or Clinical stage T2b/c Clinical stage T2b/c Additionally, patients will be required to meet the following criteria Age ≥18 KPS≥70 Prostate volume ≤ 60cc (cytoreductive androgen deprivation therapy prior to brachytherapy of ≤ 6 months duration will be allowed to achieve this goal). For patients with a prostate volume between 50-60ccs, hormone therapy will be at the discretion of the physician. International Prostate Symptom Score ≤15
Exclusion Criteria:
Prior prostate surgery (including TURP) Prior history of chronic prostatitis or urethral stricture Inflammatory bowel disease Prior history of pelvic radiotherapy Unable to give informed consent Metastatic disease.
